WG
RAPP

Winton Group’s Rapport Therapeutics RAPP Stock Holding History

Winton Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-24,127
Closed -$494K – 820
2024
Q3 		$494K Buy
+24,127
New +$518K 0.03% 446

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Winton Group's RAPP Position: Q4 2024 in Review

Winton Group sold out of Rapport Therapeutics (RAPP) in Q4 2024, closing a stake of 24,127 shares — an estimated $494K sold.

Winton Group first reported a position in RAPP in Q3 2024 and held it in 1 quarter. The position peaked at $494K in Q3 2024. 70 funds tracked by Wall St. Rank hold RAPP as of Q4 2024.

  • Winton Group reported no remaining Rapport Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Winton Group sold 24,127 Rapport Therapeutics shares in Q4 2024, an estimated $494K.
  • Winton Group first reported a position in Rapport Therapeutics in Q3 2024 and held it in 1 quarter.
  • Winton Group's Rapport Therapeutics position peaked at $494K in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2024.

Based on Winton Group's 13F filing for Q4 2024, filed 12 Feb 2025.